https://scholars.lib.ntu.edu.tw/handle/123456789/494981
標題: | LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts | 作者: | Ramalingam S CHIH-HSIN YANG Lee C.K Kurata T Kim D.-W John T Nogami N Ohe Y Jänne P.A. |
公開日期: | 2016 | 出版社: | Elsevier Inc | 卷: | 11 | 期: | 4 | 來源出版物: | Journal of Thoracic Oncology | URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84995428398&doi=10.1016%2fS1556-0864%2816%2930324-0&partnerID=40&md5=382c85073757c07a5fe44a9d9ff43993 https://scholars.lib.ntu.edu.tw/handle/123456789/494981 |
ISSN: | 1556-0864 | DOI: | 10.1016/S1556-0864(16)30324-0 | SDG/關鍵字: | epidermal growth factor receptor; osimertinib; advanced cancer; adverse event; adverse outcome; Article; Asian; cohort analysis; controlled clinical trial; controlled study; diarrhea; drug dose reduction; drug efficacy; drug safety; EGFR gene; exon; female; follow up; gene deletion; gene mutation; human; major clinical study; male; mutational analysis; non small cell lung cancer; outcome assessment; overall survival; paronychia; phase 1 clinical trial; priority journal; progression free survival; stomatitis; treatment duration; treatment response |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。